181 related articles for article (PubMed ID: 25845873)
1. Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Pain JB; Lê MP; Caseris M; Amiel C; Lassel L; Charpentier C; Desnoyer A; Farnoux C; Pialoux G; Descamps D; Peytavin G
Antimicrob Agents Chemother; 2015; 59(6):3660-2. PubMed ID: 25845873
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
4. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa.
Mpofu R; Kawuma AN; Wasmann RE; Akpomiemie G; Chandiwana N; Sokhela SM; Moorhouse M; Venter WDF; Denti P; Wiesner L; Post FA; Haas DW; Maartens G; Sinxadi P
Br J Clin Pharmacol; 2024 May; 90(5):1247-1257. PubMed ID: 38332460
[TBL] [Abstract][Full Text] [Related]
5. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
[No Abstract] [Full Text] [Related]
6. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.
Parant F; Miailhes P; Brunel F; Gagnieu MC
Ther Drug Monit; 2019 Aug; 41(4):444-451. PubMed ID: 30817698
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
Smolders EJ; Colbers EP; de Kanter CT; Velthoven-Graafland K; Drenth JP; Burger DM
J Antimicrob Chemother; 2017 Feb; 72(2):486-489. PubMed ID: 27798211
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Punyawudho B; Thammajaruk N; Thongpeang P; Matthews G; Lewin SR; Burger D; Ruxrungtham K; Avihingsanon A
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):947-54. PubMed ID: 26308175
[TBL] [Abstract][Full Text] [Related]
10. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Auclair M; Guénantin AC; Fellahi S; Garcia M; Capeau J
PLoS One; 2020; 15(1):e0226924. PubMed ID: 31971958
[TBL] [Abstract][Full Text] [Related]
11. Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Baptiste SL; Taro TB; Etya'ale HM
Curr Opin HIV AIDS; 2019 Jan; 14(1):7-12. PubMed ID: 30451698
[TBL] [Abstract][Full Text] [Related]
12. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
16. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
Imaz A; Martinez-Picado J; Niubó J; Kashuba AD; Ferrer E; Ouchi D; Sykes C; Rozas N; Acerete L; Curto J; Vila A; Podzamczer D
J Infect Dis; 2016 Nov; 214(10):1512-1519. PubMed ID: 27578849
[TBL] [Abstract][Full Text] [Related]
17. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Lanzafame M; Lattuada E; Nicolè S; Rigo F; Cucchetto G; Concia E; Vento S
Int J STD AIDS; 2017 Jun; 28(7):726-728. PubMed ID: 27789848
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Romero-León JM; Gálvez-Contreras MC; Díez-García LF
Rev Esp Cardiol (Engl Ed); 2016 May; 69(5):529-30. PubMed ID: 27012681
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
